366 related articles for article (PubMed ID: 7845675)
21. Mutation of RET codon 768 is associated with the FMTC phenotype.
Boccia LM; Green JS; Joyce C; Eng C; Taylor SA; Mulligan LM
Clin Genet; 1997 Feb; 51(2):81-5. PubMed ID: 9111992
[TBL] [Abstract][Full Text] [Related]
22. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
Frank-Raue K; Höppner W; Frilling A; Kotzerke J; Dralle H; Haase R; Mann K; Seif F; Kirchner R; Rendl J; Deckart HF; Ritter MM; Hampel R; Klempa J; Scholz GH; Raue F
J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
[TBL] [Abstract][Full Text] [Related]
23. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
24. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
[TBL] [Abstract][Full Text] [Related]
25. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
[TBL] [Abstract][Full Text] [Related]
26. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas.
Zedenius J; Larsson C; Bergholm U; Bovée J; Svensson A; Hallengren B; Grimelius L; Bäckdahl M; Weber G; Wallin G
J Clin Endocrinol Metab; 1995 Oct; 80(10):3088-90. PubMed ID: 7559902
[TBL] [Abstract][Full Text] [Related]
27. RET proto-oncogene mutations in French MEN 2A and FMTC families.
Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM
Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109
[TBL] [Abstract][Full Text] [Related]
28. Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis.
Peacock ML; Borst MJ; Sweet JD; Decker RA
Hum Mutat; 1996; 7(2):100-4. PubMed ID: 8829625
[TBL] [Abstract][Full Text] [Related]
29. A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.
Alemi M; Lucas SD; Sällström JF; Bergholm U; Akerström G; Wilander E
Oncogene; 1997 May; 14(17):2041-5. PubMed ID: 9160884
[TBL] [Abstract][Full Text] [Related]
30. The RET proto-oncogene and cancer.
Donis-Keller H
J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.
Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S
J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371
[TBL] [Abstract][Full Text] [Related]
32. [Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
Belli S; Storani ME; Dourisboure RJ; Podestá EJ; Solano AR
Medicina (B Aires); 2003; 63(1):41-5. PubMed ID: 12673960
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
34. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
[TBL] [Abstract][Full Text] [Related]
35. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
[TBL] [Abstract][Full Text] [Related]
36. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
37. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene.
Musholt PB; Musholt TJ; Goodfellow PJ; Zehnbauer BA; Wells SA; Moley JF
Surgery; 1997 Aug; 122(2):363-70; discussion 370-1. PubMed ID: 9288142
[TBL] [Abstract][Full Text] [Related]
38. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
39. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma.
Kimura T; Yoshimoto K; Yokogoshi Y; Saito S
Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
